2,6-二氟-4-甲氧基苯甲酸 | 123843-65-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,6-二氟-4-甲氧基苯甲酸
• 中文别名: 2,6-二氟-4-甲氧苯甲酸
• 英文名称: 2,6-difluoro-4-methoxybenzoic acid
• CAS: 123843-65-2
• 化学式: C₈H₆F₂O₃
• 分子量: 188.131
• InChiKey: LGHVYSAINQRZJQ-UHFFFAOYSA-N

物化性质

• 熔点：
  184-185°C
• 沸点：
  232.0±35.0 °C(Predicted)
• 密度：
  1.399±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  如果按照规格使用和储存，则不会分解，未有已知危险反应。避免与氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2918990090
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  请将贮藏器密封保存，并存放在阴凉、干燥处。同时，确保工作环境具有良好的通风或排气设施。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 2,6-Difluoro-4-methoxybenzoic acid
CAS-No. : 123843-65-2
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
S36/37 Wear suitable protective clothing and gloves.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C8H6F2O3
Molecular Weight : 188,13 g/mol
Component Concentration
2,6-Difluoro-4-methoxybenzoic acid
CAS-No. 123843-65-2 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Indication of immediate medical attention and special treatment needed
no data available

---

Section 5. FIRE-FIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Hydrogen fluoride
Precautions for fire-fighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at
the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and
approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the
standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use
respirators and components tested and approved under appropriate government standards such as
NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: beige
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting/freezing point Melting point/range: 184 - 188 °C
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,496
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional
waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent
and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN-Number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for users
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,6-二氟-4-甲氧基苯甲酸 在 硫酸 作用下， 以 甲醇 为溶剂， 生成 methyl 2,6-difluoro-4-methoxybenzoate
  参考文献：
  名称：

  Carboxylate derivatives comprising an ether group and liquid crystal

  摘要：

  由以下一般公式（I）表示的化合物，包含相同化合物的液晶组合物，以及使用该液晶组合物的液晶元件。其中B.sub.1和B.sub.2分别代表一个trans-1,4-环己亚基或一个1,4-苯亚基，其中六元环上至少一个氢原子可以选择性地被卤素原子取代，Y代表具有1至3个碳原子的卤素取代烷基基团，具有1至3个碳原子的卤素取代烷氧基团，氰基，氟原子或氯原子，X代表氟原子，氯原子或氢原子，R.sub.1代表具有1至10个碳原子的烷基基团或具有1至10个碳原子的烷氧基团，n和m分别独立地代表1或2，p代表0或1。本发明的化合物具有较大的介电各向异性，低阈值电压，以及阈值电压的良好温度依赖性，以及与已知液晶化合物的良好互溶性，因此包含该化合物的液晶组合物可以提供低电压操作的液晶显示元件。

  公开号：

  US06149990A1
• 作为产物：
  描述：

  3,5-二氟苯甲醚 在 盐酸 、 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 2,6-二氟-4-甲氧基苯甲酸
  参考文献：
  名称：

  Carboxylate derivatives comprising an ether group and liquid crystal

  摘要：

  由以下一般公式（I）表示的化合物，包含相同化合物的液晶组合物，以及使用该液晶组合物的液晶元件。其中B.sub.1和B.sub.2分别代表一个trans-1,4-环己亚基或一个1,4-苯亚基，其中六元环上至少一个氢原子可以选择性地被卤素原子取代，Y代表具有1至3个碳原子的卤素取代烷基基团，具有1至3个碳原子的卤素取代烷氧基团，氰基，氟原子或氯原子，X代表氟原子，氯原子或氢原子，R.sub.1代表具有1至10个碳原子的烷基基团或具有1至10个碳原子的烷氧基团，n和m分别独立地代表1或2，p代表0或1。本发明的化合物具有较大的介电各向异性，低阈值电压，以及阈值电压的良好温度依赖性，以及与已知液晶化合物的良好互溶性，因此包含该化合物的液晶组合物可以提供低电压操作的液晶显示元件。

  公开号：

  US06149990A1

文献信息

• An improved palladium(II)-catalyzed method for the synthesis of aryl ketones from aryl carboxylic acids and organonitriles
  作者：Linda Axelsson、Jean-Baptiste Veron、Jonas Sävmarker、Jonas Lindh、Luke R. Odell、Mats Larhed

  DOI：10.1016/j.tetlet.2014.02.109

  日期：2014.4

  palladium(II)-catalyzed decarboxylative protocol for the synthesis of aryl ketones has been developed. The addition of TFA was shown to improve the reaction yield and employing THF as solvent enabled the use of solid nitriles and in only a small excess. Using this method, five different benzoic acids reacted with a wide range of nitriles to produce 29 diverse (hetero)aryl ketone derivatives in up to 94% yield.

  已经开发了钯（II）催化的用于合成芳基酮的脱羧方案。显示出添加TFA可提高反应产率，并且使用THF作为溶剂使得能够使用固体腈并且仅少量使用。使用这种方法，五种不同的苯甲酸与各种腈反应，可生成29种多样的（杂）芳基酮衍生物，收率高达94％。
• [EN] QUINOLINE DERIVATIVES AS ALPHA4BETA7 INTEGRIN INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINE UTILISÉS EN TANT QU'INHIBITEURS DE L'INTÉGRINE ALPHA4BÊTA7
  申请人：GILEAD SCIENCES INC

  公开号：WO2020092375A1

  公开（公告）日：2020-05-07

  The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

  本公开提供了如下所述的化合物的化学式(I)或其药用可接受的盐。本公开还提供了包含化合物的药物组合物的制备方法，制备化合物的方法以及治疗炎症性疾病的治疗方法。
• Pd-Catalyzed Decarboxylative Cross Coupling of Potassium Polyfluorobenzoates with Aryl Bromides, Chlorides, and Triflates
  作者：Rui Shang、Qing Xu、Yuan-Ye Jiang、Yan Wang、Lei Liu

  DOI：10.1021/ol100008q

  日期：2010.3.5

  Pd-catalyzed decarboxylative cross coupling of potassium polyfluorobenzoates with aryl bromides, chlorides, and triflates is achieved by using diglyme as the solvent. The reaction is useful for synthesis of polyfluorobiaryls from readily accessible and nonvolatile polyfluorobenzoate salts. Unlike the Cu-catalyzed decarboxylation cross coupling where oxidative addition is the rate-limiting step, in

  通过使用二甘醇二甲醚作为溶剂可实现多氟苯甲酸钾与芳基溴化物，氯化物和三氟甲磺酸酯的钯催化脱羧交叉偶联。该反应可用于由容易获得的非挥发性多氟苯甲酸盐合成多氟联芳基。与其中氧化加成是限速步骤的Cu催化的脱羧交叉偶联不同，在Pd催化的形式中，脱羧是限速步骤。
• 8-Substituted isoquinoline derivative and the use thereof
  申请人：Kaneko Shunsuke

  公开号：US20100261701A1

  公开（公告）日：2010-10-14

  The present invention relates to a compound represented by the following formula (1): wherein D 1 , A 1 , D 2 , R 1 , D 3 , and R 2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.

  本发明涉及一种由以下式（1）表示的化合物： 其中D1，A1，D2，R1，D3和R2分别具有与本说明书中定义的相同含义或其盐。由式（1）表示的化合物或其盐具有IKKβ抑制活性等，对于预防和/或治疗IKKβ相关疾病或症状等方面是有用的。
• AROMATIC COMPOUND
  申请人：TAKEDA PHARMACEUTICAL COMPANY LIMITED

  公开号：US20160115128A1

  公开（公告）日：2016-04-28

  Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

  提供一种具有GPR40激动剂活性和GLP-1分泌素作用的新型芳香环化合物。具有下式表示的化合物： 其中每个符号如描述中所述，或其盐具有GPR40激动剂活性和GLP-1分泌素作用，对于预防或治疗癌症、肥胖症、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌少症等疾病具有用处，并且具有卓越的疗效。